Infertility Drugs Market Increasing Research & Development for More Effective Treatment with Lesser Side-Effects to Reduce Infertility

Infertility is a global health issue as its affects both men and women. Infertility in females occur due to increasing age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages whereas in males infertility occur due to erectile dysfunction, low sperm count, abnormal sperms, etc. Increasing prevalence of infertility is expected to propel demand for the infertility drugs. According to World Health Organization (WHO) 2012 report, infertility affects one out of four couples in emerging economies. Many researchers are working towards finding an efficient treatment for the infertility. For instance, in 2018 at Ben-Gurion University (BGU), Israel researchers were developing a new, single-dose infertility treatment based on a new compound. The new treatment, developed by the BGU researchers, stimulates the expression of the telomerase and re-elongates the telomeres, protecting the cells from damage.

Request Sample Copy of Research Report @ http://bit.ly/2W4lxIW

The global infertility drugs market size was valued at US$ 3.8 billion in 2017, and is expected to witness a CAGR of 5.8% over the forecast period (2019 – 2026).

Increasing Research & Development for More Effective Treatment with Lesser Side-Effects to Reduce Infertility is expected to Drive Growth of the Infertility Drugs Market

The infertility drugs market size is expected to witness significant growth, owing to the rising research and developmental studies for more effective treatment to achieve pregnancy and live births. For instance, in 2014, a team of researchers at National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) found that women treated with Letrozole have high rates of ovulation and live births than women treated with the standard drug, Clomiphene. Furthermore, among women who received Letrozole, 27.5% of them eventually had a live birth and women who received clomiphene, only 19.1% them experienced a live birth. The cumulative ovulation rate was higher for the Letrozole group, with ovulation occurring 61.7% of the time, and the women in the clomiphene group ovulated 48.3% of the time.

Market Dynamics

Increasing prevalence of infertility in couples is highly contributing to infertility drugs market size. For instance, According to Centres for Disease Control and Prevention (CDC) report of 2018, about 6% of women aged 15 to 44 years in the U.S. were unable to get pregnant after one year of trying (infertility). Also, about 12% of women aged 15 to 44 years in the U.S. have difficulty getting pregnant or carrying a pregnancy to term. Infertility also affects rising number of men. According to the same source, almost 9% of men aged 25 to 44 years in the U.S. reported that they required medical help for reproduction.

Inquire Here Before Purchase of Research Report @ http://bit.ly/2Z1PvPH

Infertility Drugs Market - Competitive Landscape

Key players operating in the global infertility drugs market include Merck & Co., Ferring Pharmaceuticals, LIVZON Pharmaceutical Group Inc., Abbott Laboratories, Bayer AG, and Zydus Pharmaceuticals.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.